Literature DB >> 3278870

New enema treatments for inflammatory bowel disease.

L C Karp1, S R Targan.   

Abstract

Two new preparations are under clinical trial for use in the treatment of ulcerative proctitis and left-sided colitis. One is 5-aminosalicylate, a component of sulfasalazine. This substance has virtually no immunomodulating capabilities. Evidence for efficacy equal to that of sulfasalazine in acute colitis has been obtained but its role in preventing recurrences is unknown. The other substance is tixocortol, a rapidly metabolized steroid, which has local antiinflammatory activity. Specific procedures of preparation and dosage remain to be established. Both preparations are administered as enemas.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3278870     DOI： 10.1007/bf01538136

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  7 in total

1.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

2.  Sulfasalazine-induced exacerbation of ulcerative colitis.

Authors:  A G Schwartz; S R Targan; A Saxon; W M Weinstein
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

Review 3.  Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

4.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

5.  Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application.

Authors:  P Larochelle; P Du Souich; E Bolte; J Lelorier; R Goyer
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

6.  Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by peripheral blood and intestinal mononuclear cells from control and inflammatory bowel disease patients.

Authors:  R P MacDermott; M G Kane; L L Steele; W F Stenson
Journal:  Immunopharmacology       Date:  1986-04

7.  Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes.

Authors:  F Shanahan; A Niederlehner; R P MacDermott; W F Stenson; M G Kane; S Targan
Journal:  Immunopharmacology       Date:  1986-04
  7 in total
  3 in total

1.  Enemas for IBD maintenance therapy.

Authors:  L R Sutherland; F Martin
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

Review 2.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

3.  Calcium alginate beads as core carriers of 5-aminosalicylic acid.

Authors:  S Y Lin; J W Ayres
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.